ERBA Diagnostics, Inc. Announces Timeframe within Which It Intends to File Its Annual Report on Form 10-K

Business Wire

MIAMI LAKES, Fla.--(BUSINESS WIRE)--

ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, announced that it intends to file its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission (the “SEC”) on Monday, April 14, 2014.

Pursuant to Rule 12b-25 under the Securities Exchange Act of 1934, by virtue of having timely filed a Notification of Late Filing on Form 12b-25 with the SEC, ERBA Diagnostics had received an extension until April 15, 2014 to file its Annual Report on Form 10-K for the year ended December 31, 2013, which deadline ERBA Diagnostics intends to beat.

As previously disclosed, ERBA Diagnostics had delayed the filing of its Annual Report on Form 10-K because of unforeseen delays in connection with completing and filing its consolidated financial statements and the accompanying footnotes, which include ERBA Diagnostics’ recently acquired subsidiaries – Drew Scientific, Inc. and JAS Diagnostics, Inc.

About ERBA Diagnostics, Inc.

ERBA Diagnostics, Inc. (www.erbadiagnostics.com), headquartered in Miami Lakes, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, clinical chemistry, hematology and diabetes through its six subsidiaries – Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe), ImmunoVision, Inc. (U.S.), Drew Scientific, Inc. (U.S.), JAS Diagnostics, Inc. (U.S.), and Erba Diagnostics Mexico S.A. (Latin America).

Safe Harbor Statement

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect the business and prospects of ERBA Diagnostics, including, without limitation, the risks and uncertainties that: ERBA Diagnostics’ financial results may take longer to prepare than anticipated; ERBA Diagnostics may not be able to file its Annual Report on Form 10-K for the year ended December 31, 2013 on or prior to the timeframe set forth above; ERBA Diagnostics’ integration of its recently acquired subsidiaries – Drew Scientific, Inc. and JAS Diagnostics, Inc. – into ERBA Diagnostics may take longer than anticipated; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. See also the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2012, filed with the SEC, for further discussion of certain risks and uncertainties that could materially and adversely affect our business, operating results or financial condition. Many of these factors are beyond our control. In addition to the risks and uncertainties set forth above, investors should consider the economic, competitive, governmental, technological and other risks and uncertainties discussed in the Company’s filings with the SEC, including, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in such filings.

Contact:
ERBA Diagnostics, Inc.
Mohan Gopalkrishnan, 305-418-2320
Vice President – Operations
View Comments (0)